Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human SAR443579 in R/R AML, B-ALL, HR-MDS, BPDCN
2023-508357-58-00Phase 2Completed
- Sponsor
- Sanofi
- Start
- Mar 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 5
01
Overview
Phase 2, open-label trial of SAR443579 in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) and 1 more (4 arms), sponsored by Sanofi. Primary endpoints: Incidence of dose-limiting toxicity (DLT) – Escalation Part, Incidence of DLT in Japanese participants – Japan Cohort C and 2 more. Started Mar 2024; status: completed.
02
Drugs
SAR443579
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)Blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Beyond the preview
Go deeper on 2023-508357-58-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508357-58-00.